Abstract. Thyroid transcription factor-1 (TTF-1) reportedly possesses oncogenic and suppressive roles within the same tumor type and may play a dual function in the progression of lung cancer. Immunohistochemistry (IHC) and mRNA in situ hybridization (ISH) are commonly used methods for detecting protein or mRNA expression. The present study compared the concordance rate of the two methods in the evaluation of thyroid transcription factor-1 (TTF-1) expression in non-small cell lung carcinoma (NSCLC) using tissue microarray-based IHC and mRNA ISH. TTF-1 protein and mRNA expression levels were examined in 196 cases of NSCLC. The IHC and mRNA ISH agreement was 91.3% (179/196), and near-perfect agreement was observed between the two methods (κ-coefficient, 0.848). There was no significant difference between IHC and mRNA ISH, as analyzed by the McNemar-Bowker test (P=0.219). The present findings proved that IHC is comparable to mRNA ISH for evaluating TTF-1 expression in NSCLC. These two methods can be used to detect TTF-1 expression in future studies.
Introduction
As the primary cause of cancer-associated mortality globally, lung cancer is an important public health problem. In men, lung cancer is ranked first among the commonly observed malignant tumors, while in females, the disease is ranked second or third in the majority of developed countries. The 5-year survival rate is ~15% and the cure rate remains low (1) . Therefore, the elucidation of the tumorigenesis of lung carcinoma is of paramount importance for the improvement of public health.
Thyroid transcription factor-1 (TTF-1), also known as NKX2-1 or TITF-1, is mapped to chromosome 14q13 and the protein a 38-kDa transcription factor that is normally expressed in the thyroid gland, lungs and brain. This type of exhibits significant functions in the development, cell growth and differentiation processes. TTF-1 reportedly possesses oncogenic and suppressive functions within the same tumor type and may play a dual function in the progression of lung cancer (2) . TTF-1 is also used in the differentiation between primary and metastatic lung tumors (3, 4) .
Immunohistochemistry (IHC) has been used (5-7) to detect TTF-1 expression in lung carcinomas. TTF-1 expression differs among the subtypes of lung carcinoma, with strong expression in lung adenocarcinoma and small cell lung carcinoma (SCLC), and weak or no expression in squamous cell lung carcinoma and large cell lung carcinoma. In our previous studies, mRNA in situ hybridization (ISH) was used to detect TTF-1 mRNA expression in different subtypes of lung cancer. The TTF-1 protein expression level detected by IHC is consistent with that detected by mRNA ISH (8) . However, no comparison of the statistical significance of the two methods has been performed.
In the present study, TTF-1 expression was investigated using IHC and mRNA ISH, and the concordance rate of the two methods was compared for detecting TTF-1 expression in non-SCLC (NSCLC).
Materials and methods

Patients.
A total of 196 patients with NSCLC who were treated in Nanfang Hospital (Southern Medical University and Guangdong Provincial Institute of Nephrology, Guangzhou, Guangdong, China) between January 2000 and December 2010 were selected for this study. 
IHC and ISH in the tissue microarray (TMA).
A TMA was constructed from the 196 paraffin-embedded blocks according to a previously described procedure (10) (11) (12) . Four tissue cores selected from each sample were used to construct a 30x30 matrix microarray. In the final row of the microarray, 16 cores were used as sample location indicators. Sections (4-µm thick) were cut from the TMA blocks and used for the IHC and mRNA ISH labeling.
For IHC, TMA sections (4-µm thick) were stained with mouse anti-human TTF-1 monoclonal antibody (clone 8G7G3/1; Dako, Carpinteria, CA, USA) using the standard streptavidin-biotin complex method according to the manufacturer's instructions.
For mRNA ISH, a TTF-1 mRNA-specific oligonucleotide probe designed by Bioasia Co., Ltd., (Shanghai, China) was used to detect TTF-1 mRNA expression in the TMA samples. The sequence of the probe was 5'-GCCGACAGGTACTTCT-GTTGCTTGAAGCGT-3'. The probe was labeled with digoxin on the 3' and 5' ends. TMA sections (4-µm thick) were deparaffinized, rehydrated, rinsed in phosphate-buffered saline (PBS) and digested with pepsin at 37˚C for 20 min. The slides were hybridized with the riboprobe at 38˚C for 16 h. The hybridization samples were then washed sequentially in 2X sodium chloride and sodium citrate (SSC) at 37˚C for 5 min and in 0.5X SSC at 37˚C for 30 min. The slides were treated with 3% hydrogen peroxide to inactivate the endogenous peroxidase. Pepsin diluted with 3% citric acid was subsequently used to expose mRNA fragments. The sections were hybridized with a probe diluted with hybridization solution for 16 h at 38˚C. The hybridization samples were sequentially washed three times in 2X SSC for 5 min at 37˚C, twice in 0.5X SSC for 5 min at 37˚C and once in 0.2X SSC for 15 min at 37˚C.
The hybridized probe was detected using an in situ hybridization detection kit (Wuhan Boster Biological Technology, Ltd., Wuhan, China) according to the manufacturer's instructions (13) . Briefly, the slides were incubated with blocking reagent for 30 min at 37˚C, and then with biotin-labeled sheep antidigoxigenin for 1 h at 37˚C. The slides were sequentially washed with 0.5 M PBS at 37˚C for 5 min, and then incubated with streptavidin-biotin complex for 30 min and washed four times in 0.5 M PBS for 5 min. Finally, the slides were incubated with biotin peroxidase for 30 min at 37˚C and washed four times in 0.5 M PBS for 5 min. The peroxidase reaction was enhanced using 3,3'-diaminobenzidine. The IHC and ISH slides were counterstained with hematoxylin and cover-slipped.
Two cases of normal lung tissue were used as internal positive controls for IHC and ISH. PBS or hybridization solution was used to replace the primary antibody or the probe in order to serve as negative controls.
Analysis of IHC and mRNA ISH slides. The samples were analyzed under a 40X objective lens using a BX51 light microscope (Olympus, Tokyo, Japan). A total of 20 fields were randomly selected from four randomly chosen representative tissue cores of a specimen on the TMA. In total, 200 tumor cells were observed. Those with dark brown particles in the nuclei or cytoplasm were considered to demonstrate positive protein or mRNA expression. Two independent analysts assessed IHC and ISH staining effects.
TTF-1 IHC and ISH staining was recorded as no expression (absent staining, -), low expression (≥30% of tumor cells with weak staining intensity, +) or high expression (≥30% of tumor cells with strong staining intensity, ++). No expression was considered as negative, while low or high expression was considered as positive.
Statistical analysis.
Comparisons between IHC and mRNA ISH methods were analyzed using the McNemar-Bowker test. Concordance data obtained from IHC and mRNA ISH were determined. The κ statistic method was used to measure the agreement of positive ratios between the two assays. The κ statistic evaluates the level of agreement following adjustment for agreement expected to occur by chance alone, with a κ-coefficient of >0.80 indicating near-perfect agreement, 0.61-0.80 indicating substantial agreement, 0.41-0.60 indicating moderate agreement, 0.21-0.40 indicating fair agreement, >0-0.20 indicating slight agreement and 0 indicating no agreement or a random association (14) . SPSS 13.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. P<0.05 was considered to indicate a statistically significant difference.
Results
In the 196 cases of NSCLC detected by IHC and mRNA ISH using TMAs, the two techniques agreed that 109 were TTF-1-negative (-), 27 exhibited low expression (+) and 43 exhibited high expression (++). Representative IHC images are shown in Fig. 1 and mRNA ISH images are shown in Fig. 2 . In the 46 cases detected with ++ TTF-1 protein expression on IHC, 43 were ++ and 3 were +, as detected by mRNA ISH. No cases were negative when detected by mRNA ISH. Of the 50 cases detected with ++ TTF-1 mRNA expression on ISH, 43 were ++, 4 were + and 3 were negative, as detected by IHC. The agreement between IHC and mRNA ISH was near-perfect at 91.3% (179/196), with a κ-coefficient of 0.848 (Table I) . There was no significant difference between the two methods on the McNemar-Bowker test (P=0.219) ( Table I) .
mRNA ISH ---------------------------------------------------------
Discussion
TMAs, also known as tissue chips, are a novel technology that were invented in 1998 by Konenen et al (15) based on cDNA microarrays. This technique has a high throughput and is considered to be a resource-conserving technology in which tens of thousands of typical minute cylindrical tissue samples or cells from numerous tumor types are transferred to a new paraffin block. TMA can be used to detect DNA, RNA or proteins in a range of clinical or basic studies (16) (17) (18) . In the present study, IHC and mRNA ISH were used to detect TTF-1 gene expression in NSCLC. The McNemar-Bowker test demonstrated that there was no significant difference between the two methods (P=0.219), and the κ-test revealed near-perfect agreement between them (κ-coefficient, 0.848). This finding shows that the highly conserved transcription factor TTF-1 is crucial at the protein and mRNA levels in lung cancer development and progression.
With the development and progression of scientific technology of targeted agents in NSCLC, the majority of patients are not considered suitable for molecularly targeted therapy, as they do not express any presently known genetic alterations that make them suitable candidates for such treatment (19) .
According to the central dogma of genetics, genes are first transcribed into mRNA and then translated into proteins. In the present study, the TTF-1 gene status was detected and analyzed at the transcriptional level using mRNA ISH and at the translational level using IHC. The concordance rate of the two methods was near-perfect (91.3%; κ-coefficient, 0.848; P=0.219). However, of the 50 cases with ++ TTF-1 mRNA expression, 3 cases were negative on IHC. Of the 46 cases with ++ TTF-1 protein expression, no cases were negative on mRNA ISH. This finding indicates that the transcriptional step is the crucial process prior to translation. Similar to TTF-1 protein expression, positive TTF-1 mRNA expression in NSCLC indicates a good prognosis in lung cancer patients. The expression patterns of TTF-1 protein and mRNA in the present study are consistent with those of our previous studies (10, 11) . TTF-1 and p63 immunostaining has been utilized successfully in previous studies (20, 21) to facilitate pathological differentation between small cell carcinoma and poorly differentiated pulmonary SCC using cytological samples. Kapila et al (20) were able to catergorize NSCLC samples using a restricted panel of antibodies. The authors were also able to differentiate between adenocarcinoma and SCC samples. Furthermore, Kalhor et al (21) employed TTF-1 and p63 immunostaining to identify primary lung tumors, which could be further catergorized as SCCs.
During the construction of the TMAs, representative tumor areas were carefully chosen from the donor blocks. The four cores biopsied in each donor block highly represented the characteristics of each lung cancer. All 196 samples were detected simultaneously on a single glass slide to ensure a comparable and consistent data analysis. Furthermore, additional studies are required to authenticate the possible diagnostic value of the current findings. For example, future studies should include intraobserver and interobserver variability in their evaluation; sensitivity, specificity, predictive values for the presence of TTF-1 positivity; and possibly a correlation between the different growth patterns, TTF-1 gene expression and TTF-1 amplification.
In conclusion, TTF-1 expression, as detected by IHC and mRNA ISH using TMA technology, could reveal the biological features of samples and detect gene expression.
